Evidence map›Paper›PMID 39192241›Full record

ArticleBMC psychiatry2024

Developing a validated methodology for identifying clozapine treatment periods in electronic health records.

Aviv Segev, Risha Govind, Ebenezer Oloyede, Hamilton Morrin, Amelia Jewell, Rowena Jones, Laura Mangiaterra, Stefano Bonora, Ehtesham Iqbal, Robert Stewart and 2 more

Abstract readValidation Study
In one paragraph

Article in BMC psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aviv Segev *NIHR Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK. aviv.segev@kcl.ac.uk.ORCID 0000-0002-9550-3895
Risha Govind *NIHR Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.ORCID 0000-0001-9925-7866
Ebenezer OloyedePharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.ORCID 0000-0003-1352-4017
Hamilton MorrinDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0002-7801-0212
Amelia JewellNIHR Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.ORCID 0000-0002-0887-2159
Rowena JonesBirmingham and Solihull Mental Health Foundation Trust, Birmingham, UK.ORCID 0000-0002-3426-1394
Laura MangiaterraNIHR Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.
Stefano BonoraNIHR Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.
Ehtesham IqbalInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0001-9477-9745
Robert StewartNIHR Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.ORCID 0000-0002-4435-6397
Matthew BroadbentNIHR Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.
James H MacCabeDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0002-6754-1018

Funding

Medical Research Council MR/W014386, MR-VO49879/1National Institute for Health and Care Research NIHR131157, NIHR150308, NIHR131175
6 · The paper itself

Abstract

backgroundClozapine is the only recommended antipsychotic medication for individuals diagnosed with treatment-resistant schizophrenia. Unfortunately, its wider use is hindered by several possible adverse effects, some of which are rare but potentially life threatening. As such, there is a growing interest in studying clozapine use and safety in routinely collected healthcare data. However, previous attempts to characterise clozapine treatment have had low accuracy.

aimTo develop a methodology for identifying clozapine treatment dates by combining several data sources and implement this on a large clinical database.

methodsNon-identifiable electronic health records from a large mental health provider in London and a linked database from a national clozapine blood monitoring service were used to obtain information regarding patients' clozapine treatment status, blood tests and pharmacy dispensing records. A rule-based algorithm was developed to determine the dates of starting and stopping treatment based on these data, and more than 10% of the outcomes were validated by manual review of de-identified case note text.

resultsA total of 3,212 possible clozapine treatment periods were identified, of which 425 (13.2%) were excluded due to insufficient data to verify clozapine administration. Of the 2,787 treatments remaining, 1,902 (68.2%) had an identified start-date. On evaluation, the algorithm identified treatments with 96.4% accuracy; start dates were 96.2% accurate within 15 days, and end dates were 85.1% accurate within 30 days.

conclusionsThe algorithm produced a reliable database of clozapine treatment periods. Beyond underpinning future observational clozapine studies, we envisage it will facilitate similar implementations on additional large clinical databases worldwide.

Indexed as

AlgorithmsAntipsychotic AgentsClozapineElectronic Health RecordsAdultDatabases, FactualFemaleHumansLondonMaleMiddle AgedSchizophrenia, Treatment-ResistantAntipsychotic AgentsClozapineAlgorithmClozapineCRISDatabasesEHRMaudsleyPsychosisSchizophrenia

Identifiers

PMID39192241
PMCPMC11351314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.